C2N Diagnostics takes Alzheimer’s blood testing younger as FDA clears PrecivityAD2 from age 40
C2N Diagnostics’ FDA-cleared PrecivityAD2 combines amyloid and tau measurements in a mass-spectrometry test intended to aid assessment of symptomatic adults aged 40 and older.
